Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Among 106 patients with Hodgkin's lymphoma in stage IIIB and IVB treated from September 1969 to June 1977 by a working team for hematology and oncology at the clinic and outpatients clinic of the Medical School of Erfurt, there were two cases (=1.9%) showing a final transition to leukaemia with immature cells. A third neoplasia which had developed in a former field of irradiation was additionally observed in one patient. The various possibilities arising from an oncologic effect of ionizing rays and those substances having a cytostatic effect are discussed. After frequent reports on the occurrence of secondary tumours following intensive radiological and cytostatic therapy of advanced Hodgkin's lymphoma the enhanced risk of a secondary tumour being induced by this combined therapy cannot be excluded. Various conclusions are drawn from that by the authors.
 ...
PMID:[The appearance of immature cell leukemias after radiologic and cytostatic intensive therapy of Hodgkin's lymphoma]. 8 Mar 62

An immunocytochemical and ultrastructural study using the Fab fragment of an anti-human Ig antibody labelled with peroxidase was carried out on affected lymph nodes from five Hodgkin's disease patients. The tumor cells (Reed-Sternberg cells and Hodgkin cells) showed an exclusively hyaloplasmic granular staining. By comparing these grains with ribisome staining. By comparing these grains with ribosome staining of the endoplasmic reticulum of plasma cells it could be suggested that they are free risobomes. This ribosomal Ig synthesis is a major argument for the B lymphocyte nature of Reed-Sternberg and Hodgkin cells. The total absence of vacuole staining allows us to conclude that these cells are not histiocytic or macrophage derivatives.
 ...
PMID:Ultrastructural and immunocytochemical localization of immunoglobulin synthesis in tumor cells in Hodgkin's disease. 8 23

The effectiveness of computed body tomography (CT) in the workup, treatment planning, and follow-up of 38 patients with Hodgkin's disease and 59 with non-Hodgkin's lymphoma was analyzed. CT scanning can frequently define lymphoma in the retroperitoneum, and occasionally in mesenteric lymph nodes, spleen, and liver. These data are useful for staging, for radiotherapy treatment planning, and in monitoring response to radiotherapy or chemotherapy. CT was found to be particularly useful in patients with large mediastinal masses. Analysis of patterns of intrathoracic spread allowed modification of treatment techniques in 60% of patients with spread along the chest wall, in order to reduce the volume of normal tissue irradiated, while obtaining adequate dose distributions within the tumor volume. It is anticipated that chest CT scanning in lymphoma patients will lead to improved tumor control and reduction of radiation complications.
 ...
PMID:Contribution of computed tomography to the treatment of lymphomas. 9 88

Therapeutic results of Hodgkin's disease could be significantly improved by the introduction of megavoltage radiotherapy equipment and more profound knowledge about this disease. By this way, five year survival rates of 70% can be achieved for all stages and up to 100% for the early stages. The wide field technique enables the coverage of all lymph nodes with protection of non involved organs. Simultaneously, these improved technical conditions make optimal radiation planning necessary which demands numerous technical auxiliaries. Radiation type and radiation energy are important preconditions for the therapy; production and usage of shilding blocks are necessary for individual performance. The principle for optimal radiation dose distribution are measurements and calculations on the phantom which are now included in computer programs. Nevertheless, radiation of large volumes represent a high stress for the patient. Despite the improvement of the therapeutic results there are except the acute radiation side effects, also irreversible alterations. These can be analysed only after long time observations and has to be balanced with the therapeutic results. The knowledge of these side effects is very important for the radiologist. Beside that, the risk of induction of a second tumor has to be considered. The present possibilities of absolute control of this disease enables the overtreatment of lesions in the early stages. Therefore it has to be postulated to regard the present therapy concepts with attention and to consider the possible side effects.
 ...
PMID:[Present state of the wide-field megavoltage radiotherapy of Hodgkin's disease. Fundamentals, performance, side effects (author's transl)]. 10 Aug 27

This is a report of proven massive infiltration of Hodgkin's disease of the lung with correlative sonographic, roentgenographic, and pathologic findings. Special emphasis is placed on the difficulties in distinguishing pleural fluid from massive tumor infiltration of the lung by Hodgkin's disease.
 ...
PMID:Pitfalls in ultrasonic detection of pleural fluid. 10 26

The physiocochemical and immunological properties of alkaline phosphatase extracted from Hodgkin's nodes, non-Hodgkin's lymphoma nodes and leukemic leukocytes have been studied. The alkaline phosphatase from these three tumor types possesses the same biophysical and biochemical properties and immunological determinants as the placental alkaline phosphatase. However, it is more heat-labile than the placental isoenzyme. Immunological experiments indicate that, of these tumor types, Hodgkin's tumor contains the largest amounts of heat-labile Regan type of alkaline phosphatase.
 ...
PMID:Occurrence of heat-labile Regan type of alkaline phosphatase in hematopoietic tumors. 11 39

Testing of delayed hypersensitivity responses to recall antigens, newly encountered antigens and tumor antigens has contributed to the understanding of several immunologic factors in human neoplasia. Patients with Hodgkin's disease tend to have depressed responses to both newly encountered and recall antigens. Patients with solid tumors are more likely to be deficient only in the response to newly encountered antigens. In patients who have intact response to recall antigens, reactivity to antigen preparations from tumor and control tissue may be studied. Tumor-associated or organ-associated antigens have been demonstrated by delayed hypersensitivity responses in leukemia, Burkitt's lymphoma, malignant melanoma and carcinoma of the lung, breast, cervix uteri and intestine. Approaches to a definition of the specificity of these reactions are described. The results with these tumor antigen tests correlate strongly with the clinical course. This is a promising technique for monitoring immunotherapy. The results from tests with recall and newly encountered antigens also correlate with the clinical status and perhaps with prognosis. Various possible interpretations of these changes are discussed. Further work should be directed toward an exact definition of immunologic defects in patients with cancer and toward the use of this understanding for a rational program of immunotherapy.
 ...
PMID:Immunologic evaluation of patients with cancer by delayed hypersensitivity reactions. 12 44

Proliferative responses by blood and tumor lymphocytes to plant mitogens and allogeneic leukocyte antigens were tested concomitantly on 12 patients with Hodgkin's disease, 10 with chronic lymphocytic leukemia, and seven with non-Hodgkin's lymphomas. In 13 control studies, 3H-thymidine incorporation by blood and lymph node lymphocytes was brisk and, overall, comparable. With Hodgkin's disease, where extent of disease involvement and lymphocyte-depleted tumor histology were factors in the degree of responsiveness, incorporation was higher or at least comparable by tumor lymphocytes when compared with incorporation by autologous blood lymphocytes. Lymph node lymphocytes, especially with clinically stable disease, were more responsive than blood lymphocytes with chronic lymphocytic leukemia. Conversely, tumor lymphocytes were hyporesponsive compared with autologous blood lymphocytes with non-Hodgkin's lymphomas, where prognosis is usually less favorable than with chronic lymphocytic leukemia. Plasma from four out of 33 patients, although not lymphocytotoxic, inhibited lymphoproliferative responses.
 ...
PMID:Reactivity of lymphocytes from primary neoplasms of lymphoid tissues. 13 38

81 untreated malignant lymphomas of the neck were classified morphologically according to the German Kiel classification and to the American classification of Rappaport and Berard and these tumors were typed immunologically as to their T- or B-cell nature. Cells from 16 of these patients were subsequently grown in tissue culture for periods up to seven months. Tissue culture cells were monitored as to spontaneous variations in the morphologic cell type and to the expression of T- or B-cell surface determinants. In addition in 10 patients sera were tested for anti-Epstein-Barr virus (EBV) antibodies. The results of these investigations were correlated with the course of the individual neoplastic disease. Significantly elevated titers against EBV antigens were detected primarily in 8 of 10 patients, mainly in lymphocytic lymphomas respective lymphoplasmacytoid immunocytomas. All such neoplasms belonged immunologically to B-cell lymphomas and were readily grown in tissue culture. The morphological cell type and the expression of B-cell determinants showed some variation during the culture period. In contrast,lymphomas of EBV-negative patients or patients with low EBV-titers grew poorly in tissue culture and remained morphologically more stabile. Immunocytologically they belonged to tumors with B- and T-cell deficiency and were classified primarily as histiocytic lymphomas and as Hodgkin's lymphomas. The clinical course in slow proliferating tumors seemed to be rather disadvantageous.
 ...
PMID:[Classification of malignant lymphomas of the neck: combined morphological, immunocytological, serological and tissues culture studies (author's transl)]. 13 61

Twenty-four patients with far advanced malignant tumors, resistent to established chemotherapy,, were treated with the combination of MNU and Cyclophosphamide. The drugs were administered in six-day cycles sequentially. MNU in doses of 4 mg/kg body weight and Cyclophosphamide in doses of 8 mg/kg body weight were given. Results of treatment showed response (greater than 50% tumor regression) in 10 (42%) of the 24 treated patients. Seven remissions were complete and three partial. Patients with Hodgkin's disease, malignant melanoma and breast cancer responded to this combination chemotherapy. Objective remissions were obtained also in five of thirteen patients with primary or metastatic brain tumors and in five of nine patients with pulmonary metastases. Nausea and vomiting were the main toxic effects, especially after injections of MNU. Myelosuppression was noted in about 50% of treated patients. Since this combination of cytostatics showed significant antitumor activity, further investigations are necessary on a larger number of patients and in other types of malignant tumors.
 ...
PMID:Combination chemotherapy with 1-methyl-1-nitrosourea (MNU) and cyclophosphamide in solid tumors. 14 13


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>